Jury orders Gilead's Kite Pharma to pay $752M for CAR-T patent infringement

A California jury has ordered Gilead's Kite Pharma to pay $752 million for patent infringement. (Pixabay)

In a high-stakes patent lawsuit between CAR-T companies Bristol-Myers Squibb and Gilead Sciences, BMS has come up with a victory. 

After a two-week trial, jurors in California ordered Gilead’s Kite Pharma to pay $752 million to BMS’ Juno Therapeutics and its partners, which sued in 2017 for patent infringement.

A BMS spokesperson said the company is "pleased" with the decision, while a Gilead representative said the company is "steadfast in our opinion" that the patent isn't infringed and is invalid. Gilead said it'll address its concerns in post-trial motions and through a potential appeal. 

In its lawsuit, Juno alleged Kite scientific collaborators copied research by scientists at Sloan Kettering to advance Kite’s CAR-T work and eventually win approval for CAR-T cancer med Yescarta. In 2013, Juno exclusively licensed a patent from Sloan Kettering and the Memorial Sloan Kettering Cancer Center covering the technology.  

RELATED: Kite Pharma, Juno duke it out in court over megamillion-dollar CAR-T patent 

In 2017, Kite scored a FDA approval for Yescarta; Juno contended the company was infringing the patent it licensed by marketing the med. 

Following a series of deals, Juno is now part of Bristol-Myers Squibb. Celgene first bought the CAR-T-focused biotech for $9 billion, and BMS just closed its massive Celgene merger. Kite Pharma joined Gilead under a 2017 buyout. 

Suggested Articles

Pfizer isn't giving up in biosims. This week, it unveiled launches to three Roche blockbusters, with two already on the market.

Novo Nordisk is betting big on GLP-1 Saxenda in its global obesity push, but England's cost watchdog is unimpressed with the drug's long-term outlook.

Tecentriq didn’t show benefit against simple observation at delaying cancer recurrence or death in patients with muscle-invasive urothelial cancer.